Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
PEMETREXED, VINORELBINE, Rilvegostomig, MYCOPHENOLATE MOFETIL, ETOPOSIDE, CISPLATIN, INFLIXIMAB, CARBOPLATIN, Datopotamab deruxtecan
AstraZeneca AB
Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-positive result or high-risk pathological feature
1 trial -
PG-011Gel
Prime Medicine
Atopic Dermatitis
1 trial -
PGET
Atrium Therapeutics
Osteoarthritis
1 trial -
PH94B
Vistagen Therapeutics
Social Anxiety Disorder
1 trial -
PH94B Nasal Spray
Vistagen Therapeutics
Social Anxiety Disorder
2 trials -
PIPERACILLINE TAZOBACTAM VIATRIS 4 g/0,5 g, poudre pour solution pour perfusion, CEFAZOLIN, Placebo de Cefazoline / Piperaciline / Tazobactam
Pari Pharma GmbH
Excision-autograft surgery in burn patient
1 trial -
PLACEBO OF VANCOMYCINE = NaCl 0.9% ( oral use ), Vancomycine Viatris 500 mg poudre pour solution pour perfusion
Pari Pharma GmbH
Patients hospitalized for allogeneic hematopoietic stem cell transplantation
1 trial -
PLACEBO, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, INFLIXIMAB, DOMVANALIMAB
AstraZeneca AB
The target population of interest in this study is participants with locally advanced (Stage III), unresectable NSCLC, whose tumours express PD L1 TC ≥ 1% as assessed by a central reference laboratory using the VENTANA PD-L1 (SP263) IHC assay, and who did not progress after definitive platinum based cCRT.
1 trial -
PLACEBO, Nicetile 500 mg polvere per soluzione orale
Istituto Gentili S.r.l.
amyotrophic lateral sclerosis
1 trial -
PLASMA, Omniplasma 45-70 mg/ml oplossing voor infusie
Disc Medicine
Coagulation in pediatric cardiac surgery
1 trial -
PLERIXAFOR, Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM
Vertex Pharmaceuticals (Australia) Pty.
Transfusion-dependent β-thalassemia (TDT), Severe sickle cell disease (SCD)
1 trial -
PRAX-222
Chongqing Precision Biotech Co., Ltd
Voltage-gated sodium channel type II alpha subunit (SCN2A) developmental and epileptic encephalopathy (DEE)
1 trial -
PRAX-628, PRAX-628, PRAX-628, PRAX-628
Chongqing Precision Biotech Co., Ltd
Focal onset seizures or primary generalized tonic-clonic seizures.
1 trial -
PREDNISOLONE , Dupixent 300 mg solution for injection in pre-filled syringe, Placebo matching to dupilumab
Lacuna Pharma Pty Ltd
Bullous Pemphigoid
1 trial -
PREDNISONE, BMS-986365, ENZALUTAMIDE, ABIRATERONE, DOCETAXEL, PREDNISOLONE, ABIRATERONE, ENZALUTAMIDE
Celgene Europe Limited
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1 trial -
PREDNISONE, PREDNISONE, ARGX-113, PREDNISONE, PREDNISONE, PBO PH20 SC
argenx
Bullous Pemphigoid (BP)
1 trial -
PREDNISONE, PREDNISONE, SODIUM CHLORIDE, RITUXIMAB
Fondazione Telethon ETS
Generalized Myasthenia Gravis
1 trial -
PREDNISONE, Placebo to AIN457 150mg/1mL solution for injection in pre-filled syringe, SECUKINUMAB, PREDNISONE, Placebo to Prednisone 1 mg, 2.5mg, 5mg, 20mg hard gelatin capsule with tablet content, PREDNISONE, PREDNISONE, SECUKINUMAB, Placebo to AIN457 300mg/2mL solution for injection in pre-filled syringe
Novartis Pharmaceuticals
Giant cell arteritis (GCA)
1 trial -
PROGRAF 1 mg capsule, Envarsus 0.75 mg prolonged-release tablets
Disc Medicine
lung transplantation
1 trial -
PROTAMINE CHOAY 1000 U.A.H./ml, solution injectable
Pari Pharma GmbH
Any patients ≥18 years old, eligible for transfemoral TAVI with coverage for medical insurance
1 trial -
PTX-022
PALVELLA THERAPEUTICS, INC.
Pachyonychia Congenita
3 trials -
Paclitaxel
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
Paclitaxel Aurobindo 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Ipilimumab, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBOPLATIN, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, TAXOL 6 mg/ml, concentrato per soluzione per infusione., OPDIVO 10 mg/mL concentrate for solution for infusion., Paclitaxel-GRY® 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CISPL
Bristol-Myers Squibb Australia Pty Ltd
Stage IV Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Paclitaxel, Cisplatin Plus 5-FU (TCF)
The First People's Hospital of Lianyungang
Esophageal Cancer Stage IIB
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources